US20180280425A1 - Adjuvant composition - Google Patents
Adjuvant composition Download PDFInfo
- Publication number
- US20180280425A1 US20180280425A1 US15/531,671 US201515531671A US2018280425A1 US 20180280425 A1 US20180280425 A1 US 20180280425A1 US 201515531671 A US201515531671 A US 201515531671A US 2018280425 A1 US2018280425 A1 US 2018280425A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- seq
- rna
- cancer
- circumflex over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 239000002671 adjuvant Substances 0.000 title claims abstract description 46
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 107
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 104
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 104
- 239000000427 antigen Substances 0.000 claims abstract description 39
- 102000036639 antigens Human genes 0.000 claims abstract description 39
- 108091007433 antigens Proteins 0.000 claims abstract description 39
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 25
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 8
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 53
- 108020004414 DNA Proteins 0.000 abstract description 36
- 102000053602 DNA Human genes 0.000 abstract description 22
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 16
- 230000003389 potentiating effect Effects 0.000 abstract description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 22
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 19
- 241000712079 Measles morbillivirus Species 0.000 description 14
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108020005544 Antisense RNA Proteins 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 102100026720 Interferon beta Human genes 0.000 description 9
- 108090000467 Interferon-beta Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 8
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 101710157101 TIR domain-containing adapter molecule 1 Proteins 0.000 description 7
- 230000003393 splenic effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 6
- 108010061982 DNA Ligases Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 102000045716 human TLR3 Human genes 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- -1 linker nucleic acid Chemical class 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012097 Lipofectamine 2000 Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000017306 interleukin-6 production Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091036060 Linker DNA Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000011542 interferon-beta production Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020003213 Spliced Leader RNA Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- the present invention relates to a novel adjuvant composition and a vaccine composition comprising the adjuvant composition.
- cancer immunotherapies are conducted by administering a peptide vaccine as a cancer antigen.
- co-administration of a cancer antigen with an adjuvant that activates dendritic cells has been proposed.
- the present inventors have advanced research on adjuvants for cancer immunotherapies, and found that measles viral diRNA (defective interference RNA) functions as an adjuvant.
- the diRNA induces IFN-3 expression in human cells and enhances NK activity of NK cells, and that the diRNA administered together with a cancer antigen epitope induces marked tumor regression effect in cancer-bearing mice prepared by implanting B16 melanoma cells (Patent Literature 1).
- Non Patent Literature 1 The inventors have also identified an oligo DNA that inhibits poly(I:C)-induced TLR3-mediated IFN- ⁇ expression, and reported that the oligo DNA shares the uptake receptor with poly(I:C) and the oligo DNA taken up in cells partially colocalized with TLR3 (Non Patent Literature 1).
- the inventors have designed a new nucleic acid based on the oligo DNA described in Non Patent Literature 1 and the diRNA described in Patent Literature 1, and discovered that the nucleic acid reaches endosomal TLR3 and exhibits potent adjuvant activity (Patent Literature 2).
- Nucleic acids with adjuvant activity supplied as pharmaceuticals must comply with the GMP standard, and are hence required to be prepared by chemical synthesis.
- chemical synthetic techniques for long RNAs, such as those longer than 100 mer have not yet been established, and such RNAs are synthesized solely by in vitro transcription.
- development of a chemically synthesizable nucleic acid with potent adjuvant activity and high safety has been greatly desired to provide an adjuvant formulation as a pharmaceutical for humans.
- An object of the present invention is to provide an adjuvant composition comprising a chemically synthesizable nucleic acid having potent adjuvant activity and high safety, and a vaccine composition comprising the adjuvant composition and an antigen or an antigen component.
- the present invention was made to solve the above problems and includes the following.
- An adjuvant composition comprising a double-stranded nucleic acid comprising a single-stranded nucleic acid A consisting of a nucleotide sequence of SEQ ID NO: 3 and a single-stranded nucleic acid B of SEQ ID NO: 4.
- a vaccine composition comprising the adjuvant composition according to any one of the above (1) to (5) and an antigen or an antigen component.
- the present invention provides an adjuvant composition
- an adjuvant composition comprising a chemically synthesized nucleic acid having potent adjuvant activity and high safety.
- the nucleic acid is more stable and has fewer adverse effects than a conventional nucleic acid produced by in vitro transcription, and is thus very useful as an adjuvant for humans.
- the adjuvant composition may be combined with an antigen or an antigen component to provide an effective vaccine composition.
- FIG. 1A shows the structure of cM362-140
- FIG. 1B shows 7% urea-containing 8% PAGE of the sense and antisense RNAs of cM362-140.
- FIG. 2 shows the structure of cM362-139.
- FIGS. 3A and 3B show the stability of cM362-140 and cM362-139 in serum-containing PBS, respectively.
- FIGS. 4A and 4B show the stability of cM362-140 and cM362-139 in RNase-free water containing serum, respectively.
- FIG. 5 shows IFN- ⁇ promoter activation by cM362-140 as evaluated by reporter assay.
- FIG. 6 shows cytokine production induced by cM362-140 as evaluated in vitro using splenic dendritic cells from wild-type mice and TLR3 knockout mice.
- FIG. 7 shows cytokine production induced by intraperitoneal administration of cM362-140 to wild-type mice and TLR3 knockout mice as evaluated in vivo.
- FIG. 8 shows the tumor regression effect of cM362-140 and/or OVA in wild-type mice bearing EG7 cell tumors.
- FIG. 9 shows the detection of OVA-specific CD8 + T cells in spleen cells after administration of cM362-140 and/or OVA to wild-type mice bearing EG7 cell tumors.
- FIG. 10 shows the production levels of IFN- ⁇ in spleen cells after administration of cM362-140 and/or OVA to wild-type mice bearing EG7 cell tumors.
- FIG. 11 shows the tumor regression effect of cM362-140 in mice (wild-type mice or TICAM-1 knockout mice) bearing B16 melanoma cell (B16D8) tumors.
- the present invention provides an adjuvant composition
- a nucleic acid comprising a double-stranded RNA bound to a single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2.
- the nucleic acid contained in the adjuvant composition of the present invention is only required to comprise the double-stranded RNA bound to the single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2. It has been demonstrated that the double-stranded RNA portion of the nucleic acid of the present invention has the ability to activate TLR3, and that the single-stranded DNA portion is delivered to the endosomal compartments of dendritic cells.
- the nucleic acid of the present invention is efficiently delivered to the endosomal compartments of dendritic cells and activates TLR3, thereby stimulating the immune function.
- the nucleotide sequence of SEQ ID NO: 1 is the nucleotide residues at positions 1 to 140 in the nucleotide sequence (SEQ ID NO: 5) of the sense strand of diRNA of measles virus laboratory-adapted strain of Edmonston (ED).
- the nucleotide sequence complementary to SEQ ID NO: 1 is indicated in SEQ ID NO: 4.
- the single-stranded DNA consisting of the nucleotide sequence of SEQ ID NO: 2 may be joined to either strand of the double-stranded RNA.
- the single-stranded DNA may be directly joined to the double-stranded RNA, or alternatively the single-stranded DNA and the double-stranded RNA may be joined together via another nucleic acid (e.g., a linker nucleic acid).
- the single-stranded DNA is directly joined to the double-stranded RNA.
- the 3′ end of the single-stranded DNA may be joined to the 5′ end of the RNA, or alternatively the 5′ end of the single-stranded DNA may be joined to the 3′ end of the RNA. More preferably, the 3′ end of the single-stranded DNA is directly covalently bonded to the 5′ end of the RNA.
- the 3′ end of the single-stranded DNA is directly covalently bonded to the 5′ end of the RNA sense strand (SEQ ID NO: 1). That is, the nucleic acid of the present invention is preferably composed of the single-stranded nucleic acid A consisting of the nucleotide sequence of SEQ ID NO: 3 (a chimeric nucleic acid composed of the single-stranded DNA and the RNA sense strand) and the single-stranded nucleic acid B of SEQ ID NO: 4 (the RNA antisense strand).
- the nucleotides of the single-stranded DNA are preferably phosphorothioate-modified nucleotides (also called “sulfur-modified nucleotides”). Part or all of the nucleotides of the single-stranded DNA may be phosphorothioate modified, but preferably all of the nucleotides of the single-stranded DNA are phosphorothioate modified. Phosphorothioate modification increases nuclease resistance and enhances delivery to endosomal compartments.
- the nucleic acid of the present invention is preferably formed of two nucleic acid strands produced by chemical synthesis. That is, the above single-stranded nucleic acids A and B are preferably chemically synthesized nucleic acid strands. Unlike conventional long RNAs synthesized by in vitro transcription, the nucleic acid of the present invention is produced by sequence-specific chemical synthesis, and thus is highly useful due to several advantages: for example, the nucleic acid of the present invention can be provided in a stable, lyophilized form, and has a correctly synthesized nucleotide sequence.
- the chemical synthesis method of the nucleic acid is not particularly limited, and a conventionally known chemical synthesis method can be appropriately used. Examples of the conventional method include the phosphoramidite method etc.
- Each of the single-stranded nucleic acids may be chemically synthesized as a full-length nucleic acid. Alternatively, several fragments of each nucleic acid may be separately synthesized and linked by ligation to give the nucleic acid.
- the length (the number of bases) of each fragment is not particularly limited, but is preferably about 30 mer to about 80 mer, more preferably about 35 mer to about 70 mer, further preferably about 40 mer to about 60 mer.
- the ligation may be performed by a known ligation technique, and is preferably performed by ligation reaction mediated by a splint DNA, as described in, for example, Moore et al. (Moore M J, & Sharp P A.
- Each of the single-stranded nucleic acids that are combined together to form the nucleic acid of the present invention preferably has no phosphate group at either of the ends.
- synthesized RNA strands have triphosphoric acid attached to the 5′ end, but since the nucleic acid of the present invention is produced by chemical synthesis, the single-stranded nucleic acids that are combined together to form the nucleic acid of the present invention have no phosphate group at the 5′ end or the 3′ end.
- nucleic acid having a phosphate group attached to the 5′ end is administered to a living body at a high dose, the nucleic acid will activate the cytoplasmic RIG-I pathway to induce the production of a large amount of cytokines, and in turn will cause adverse effects (Robinson R A, DeVita V T, Levy H B, Baron S, Hubbard S P, Levine A S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst. 1976 September; 57(3): 599-602).
- the nucleic acid of the present invention can be used to provide a highly safe adjuvant composition.
- the nucleic acid of the present invention preferentially activates the TICAM-1-mediated signaling system downstream of TLR3, and does not activate the intracellular RNA sensors other than TLR3.
- the nucleic acid of the present invention has been confirmed to have no risk of inducing cytokine storm and to be thus highly safe (see Examples 5 and 7).
- the nucleic acid of the present invention has also been confirmed to be more stable than a nucleic acid with a similar structure formed of RNA strands synthesized by in vitro transcription (see Example 2).
- the nucleic acid of the present invention is delivered to the endosomal compartments of dendritic cells and activates TLR3, thereby enhancing various immune responses.
- the nucleic acid of the present invention is highly safe and stable, and is thus very useful as an active ingredient of an adjuvant composition.
- the adjuvant composition of the present invention can be formulated into a dosage form by appropriately blending the nucleic acid of the present invention with a pharmaceutically acceptable carrier or additive.
- the adjuvant composition can be formulated into an oral formulation, such as a tablet, a coated tablet, a pill, a powder, granules, a capsule, a solution, a suspension and an emulsion, or a parenteral formulation, such as an injection, an infusion, a suppository, an ointment and a patch.
- an oral formulation such as a tablet, a coated tablet, a pill, a powder, granules, a capsule, a solution, a suspension and an emulsion
- a parenteral formulation such as an injection, an infusion, a suppository, an ointment and a patch.
- the amount of the carrier or additive to be added can be determined as appropriate based on the range typically used in the pharmaceutical field.
- the carrier or additive that may be added is not particularly limited and examples thereof include various types of carriers, such as water, physiological saline, other aqueous solvents, and aqueous or oily vehicles; and various types of additives, such as excipients, binders, pH adjusters, disintegrants, absorption promoters, lubricants, colorants, flavors and fragrances.
- various types of carriers such as water, physiological saline, other aqueous solvents, and aqueous or oily vehicles
- additives such as excipients, binders, pH adjusters, disintegrants, absorption promoters, lubricants, colorants, flavors and fragrances.
- additives examples include binders such as gelatin, corn starch, tragacanth and gum arabic; excipients such as crystalline cellulose; swelling agents such as corn starch, gelatin, and alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose and saccharin; and flavors such as peppermint flavor, wintergreen oil and cherry flavor.
- a liquid carrier such as oils and fats can be further added in addition to the above types of ingredients.
- a sterile composition for injection can be formulated in accordance with the usual pharmaceutical practice, for example, by dissolving or suspending the active ingredient in a vehicle, such as water for injection, or a natural vegetable oil, such as sesame oil and coconut oil.
- a vehicle such as water for injection, or a natural vegetable oil, such as sesame oil and coconut oil.
- An aqueous liquid for injection that may be used is, for example, physiological saline or an isotonic solution containing glucose and/or other auxiliary substances (for example, D-sorbitol, D-mannitol, sodium chloride, etc.).
- the aqueous liquid for injection may be used in combination with an appropriate solubilizer, such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (e.g., polysorbate 80TM, HCO-50, etc.).
- an oily liquid that may be used is, for example, sesame oil or soybean oil.
- the oily liquid may be used in combination with a solubilizer such as benzyl benzoate and benzyl alcohol.
- buffering agents e.g., a phosphate buffer, a sodium acetate buffer, etc.
- soothing agents e.g., benzalkonium chloride, procaine hydrochloride, etc.
- stabilizers e.g., human serum albumin, polyethylene glycol, etc.
- preservatives e.g., benzyl alcohol, phenol, etc.
- the formulations produced in the above manner can be administered to, for example, humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.).
- the dose and dosing frequency of the adjuvant composition of the present invention can be determined, as appropriate, in accordance with the purpose of administration, the age, body weight, sex and past medical history of the subject, the mode of administration, etc.
- the present invention also provides a vaccine composition comprising the adjuvant composition of the present invention and an antigen or an antigen component.
- the antigen or the antigen component include a viral antigen, a bacterial antigen, a cancer antigen, a component thereof, etc.
- Preferred is a cancer antigen.
- Combined administration of the nucleic acid of the present invention and a cancer antigen has been revealed to induce marked tumor regression in tumor-bearing mice prepared by subcutaneously implanting cancer cells.
- the vaccine composition of the present invention has been confirmed to be very useful as a cancer vaccine.
- the vaccine composition of the present invention can be produced by adding an antigen or an antigen component to the adjuvant composition of the present invention.
- the vaccine composition of the present invention can be formulated into a dosage form in the same manner as in the dosage formulation of the adjuvant composition of the present invention.
- the viral antigen examples include, for example, viral antigens from adenovirus, retrovirus, picornavirus, herpesvirus, rotavirus, hantavirus, coronavirus, togavirus, flavivirus, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, reovirus, papillomavirus, parvovirus, poxvirus, hepadnavirus, spongiform virus, HIV, CMV, hepatitis A virus, hepatitis B virus, hepatitis C virus, influenza virus, measles virus, poliovirus, smallpox virus, rubella virus, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, Japanese encephalitis virus, rabies virus, influenza virus, etc., or a combination thereof.
- bacterial antigens examples include, for example, bacterial antigens from Bacillus spp., Escherichia spp., Listeria spp., Neisseria spp., Nocardia spp., Salmonella spp., Staphylococcus spp., Streptococcus spp., etc., or a combination thereof.
- cancer antigens examples include, for example, cancer antigens from leukemia, lymphoma, astrocytoma, glioblastoma, melanoma, breast cancer, lung cancer, head and neck cancer, digestive system tumors, stomach cancer, colon cancer, liver cancer, pancreatic cancer, uterine cancer, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer, penile cancer, bone tumors, blood vascular tumors, esophageal cancer, stomach cancer, rectal cancer, large intestine cancer, pancreatic cancer, gall bladder cancer, bile duct cancer, laryngeal cancer, lung cancer, bronchial cancer, bladder cancer, renal cancer, brain tumors, thyroid cancer, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, etc., or a combination thereof.
- the present invention further includes the following.
- a method for treating a cancer comprising administering the nucleic acid according to the above (1) and a cancer antigen to a mammal.
- the nucleic acid according to the above (1) for use in the treatment of a cancer.
- the single-stranded nucleic acids (S1, S2, S3, AS1, AS2 and AS3) shown in Table 1 were synthesized by GeneDesign, Inc.
- the RNA fragments were chemically synthesized using tBDMS RNA amidites, the DNA fragment was chemically synthesized using standard DNA amidites, and phosphorothioate linkages (sulfur modification) were introduced using PADS.
- the synthesis was performed based on the phosphoramidite method (Scaringe, S. A. et al, J Am Chem 1998; 120: 11820-11821) using a solid-phase carrier with optimized parameters. After completion of the synthesis, the protecting groups on the bases and on the 2′ position were removed by the usual method.
- the products were purified by reverse-phase HPLC and desalted to give the single-stranded nucleic acids.
- RNA cM362-140 The chemically synthesized long RNA cM362-140 was constructed by ligation reactions mediated by a splint DNA as described below (references: Moore M J & Sharp P A. Site-specific modification of pre-mRNA: the 2′-hydroxyl groups at the splice sites. Science 256: 992-997 (1992), and Jing Xu, Lapham J, & Crothers D M. Determining RNA solution structure by segmental isotopic labeling and NMR: Application to Caenorhabditis elegans spliced leader RNA 1. Proc. Natl. Acad. Sci. USA 93: 44-48 (1996)).
- RNA single-stranded nucleic acid A
- the ligation reactions were performed in two steps.
- S2 fragment SEQ ID NO: 7, 40 nmol
- S3 fragment SEQ ID NO: 8, 40 nmol
- a splint DNA SEQ ID NO: 12, 40-48 nmol specific for the ligation site were mixed, heated at 95° C. for 5 minutes and then slowly cooled to 4° C. to allow hybridization to take place.
- T4 DNA ligase (Takara Bio) was added and the mixture was incubated at room temperature for 16 to 22 hours.
- the ligation reaction mixture contained 15.4 M annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl 2 , 10 mM DTT, 0.1 mM ATP and ⁇ 31 U/ ⁇ L T4 DNA ligase.
- S1 fragment SEQ ID NO: 6, 40 nmol
- a splint DNA SEQ ID NO: 13, 40-48 nmol
- the second ligation reaction mixture contained 8.9 ⁇ M annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl 2 , 10 mM of DTT, 0.1 mM of ATP and ⁇ 31 U/L T4 DNA ligase.
- the derived full-length 165 mer sense RNA was isolated by 8% PAGE containing 7 M urea. After visualization by UV irradiation, the band of interest was excised and eluted with 0.3 M sodium acetate. The eluted RNA was ethanol precipitated and resuspended in RNase-free water.
- RNA was dialyzed, concentrated and precipitated with ethanol.
- concentration of RNA was determined by measuring the absorbance at 260 nm in a spectrometer. The yield was 8 to 10%.
- RNA single-stranded nucleic acid B
- AS1 SEQ ID NO: 9, 33 nmol
- AS2 SEQ ID NO: 10, 33 nmol
- AS3 SEQ ID NO: 11, 33 nmol
- two splint DNAs SEQ ID NOs: 14 and 15, 33 nmol each
- the ligation reaction mixture contained 15 ⁇ M annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl 2 , 10 mM DTT, 0.1 mM ATP and ⁇ 31 U/L T4 DNA ligase.
- the derived full-length 140 mer antisense RNA was purified by the same procedure as in the preparation of the sense RNA. The yield was 15 to 22%.
- FIG. 1A shows the structure of cM362-140
- FIG. 1B shows 8% PAGE of the 165 mer sense RNA (single-stranded nucleic acid A) and the 140 mer antisense RNA (single-stranded nucleic acid B) synthesized above.
- the sense and antisense RNAs were each detected as a single band with a size consistent with the nucleotide length.
- cM362-139 The structure of cM362-139 is shown in FIG. 2 , and the nucleotide sequence of cM362-139 is shown in Table 2.
- the single-stranded DNA (ODN+linker DNA) was synthesized by GeneDesign, Inc.
- DNA fragments covering this region of the MV genome and the T7 promoter sequence were amplified by PCR using the plasmid pCR-T7 MV as a template. The primers used are shown below.
- ODN-139 sense RNA (5′ primer) (SEQ ID NO: 19) 5′-tg taatacgactcactata gggaccagacaaagctggga-3′
- T7 promoter sequence is underlined.
- ODN-139 sense RNA (3′ primer) (SEQ ID NO: 20) 5′-ggatacagtgccctgattaa-3′
- ODN-139 antisense RNA (5′ primer) (SEQ ID NO: 21) 5′-tg taatacgactcactata ggatacagtgccctgattaa-3′
- T7 promoter sequence is underlined.
- ODN-139 antisense RNA (3′ primer) (SEQ ID NO: 22) 5′-ccgtggtcatgctccgggaccagacaaagctggga-3′
- the sense and antisense RNAs were in vitro transcribed from the PCR products using AmpliScribeTM T7 transcription kit (Epicentre Technologies) in accordance with the manufacturer's protocol. The transcribed products were isolated by 8% PAGE containing 7 M urea and purified in the same manner as in Example 1. Finally, the single-stranded DNA (ODN+linker DNA) and the sense and antisense RNAs were mixed and annealed to give cM362-139.
- cM362-140 and cM362-139 were separately dissolved at 20 ⁇ g/mL in serum-free PBS, PBS containing 10% heat-inactivated fetal bovine serum (FBS), PBS containing 10% mouse serum (MS) or PBS containing 10% human serum (HS), and incubated at 37° C. or 42° C. for 60 minutes.
- FBS heat-inactivated fetal bovine serum
- MS mouse serum
- HS human serum
- FIGS. 3A and 3B show the electrophoretic patterns of cM362-140 and cM362-139, respectively. Both nucleic acids were stable during the 30-minute incubation at 37° C., but cM362-139, which was prepared by in vitro transcription, was slightly degraded during the 30-minute incubation in PBS containing serum (FBS, MS or HS) at 42° C.
- PBS containing serum FBS, MS or HS
- the stability of the nucleic acids was examined by electrophoresis on 3% agarose gel using RNase-free water instead of PBS under the same conditions as above.
- FIGS. 4A and 4B show the electrophoretic patterns of cM362-140 and cM362-139, respectively.
- cM362-140 was stable under all the conditions, but cM362-139 was slightly degraded during incubation in the presence of serum (FBS, MS or HS).
- cM362-140 was found to be more stable than cM362-139.
- HEK293 cells (8 ⁇ 10 5 cells/well) were seeded in 6-well culture plates.
- the HEK293 cells were transfected with a human TLR3 expression vector (400 ng/well) or an empty vector (400 ng/well) together with a reporter plasmid p-125 (400 ng/well) and an internal control vector phRL-TK (20 ng/well, Promega) using Lipofectamine 2000 (Invitrogen).
- the reporter plasmid p-125 containing the human IFN- ⁇ promoter region was provided by Dr. Taniguchi (the University of Tokyo).
- Dulbecco's Modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FCS, Invitrogen) and antibiotics was used as medium.
- DMEM Dulbecco's Modified Eagle's medium
- FCS heat-inactivated fetal bovine serum
- cM362-140 Twenty-four hours after transfection, the cells were recovered, resuspended in medium and seeded in 96-well culture plates.
- the nucleic acids i.e., cM362-140, cM362-139, poly(I:C) (Amersham) and the double-stranded RNA portion (dsRNA140) of cM362-140, were separately added to a concentration of 10 ⁇ g/mL in the following manner:
- each nucleic acid was directly added to medium containing HEK293 cells expressing human TLR3,
- each nucleic acid and DOTAP liposomal transfection reagent were added to medium containing HEK293 cells expressing human TLR3, or
- each nucleic acid and Lipofectamine 2000 were added to medium containing HEK293 cells.
- Dual-Luciferase Reporter Assay System (Promega) was used for luciferase activity measurement. The luciferase activity was measured 6 hours after addition of the nucleic acids in (A) and (B) and 24 hours after addition of the nucleic acids in (C).
- the results are shown in FIG. 5 .
- the left panel shows the results of (A), the center panel shows the results of (B) and the right panel shows the results of (C).
- cM362-140 efficiently induced IFN- ⁇ promoter activation similar to cM362-139 in (A) the simple addition of cM362-140 to the extracellular matrix (medium) of the HEK293 cells expressing human TLR3, and in (B) the endosomal delivery of cM362-140 to the HEK293 cells expressing human TLR3 ( FIG. 5 , left and center panels).
- the spleen was harvested from wild-type C57BL/6J mice (WT) and TLR3 knockout mice (TLR3KO) (provided by Dr. Akira, Osaka University), and treated with collagenase.
- the splenocyte suspension was passed through a filter, erythrocytes were lysed, and the splenocytes were washed with medium.
- the splenocytes were subjected to MACS system (Miltenyi Biotech) using anti-CD11c microbeads to isolate CD11c + cells as splenic DCs.
- DMEM Dulbecco's Modified Eagle's medium
- FCS heat-inactivated fetal bovine serum
- the splenic DCs were seeded at 5 ⁇ 10 5 cells in 500 ⁇ L of medium per well in 24-well plates, then 20 ⁇ g/mL nucleic acid (cM362-140, cM362-139, poly(I:C), or dsRNA140) was added (A) alone, (B) together with DOTAP liposomal transfection reagent (Roche), or (C) together with Lipofectamine 2000 (Invitrogen), and the cells were cultured for 24 hours. After 24 hours of culture, the culture supernatants were recovered, and the production levels of TNF- ⁇ , IL-6 and IFN- ⁇ were measured.
- BD CBA Flex Set system was used for measurement of TNF- ⁇ and IL-6, and Mouse IFN- ⁇ ELISA Kit (PBL Assay Science) was used for measurement of IFN-3.
- the results are shown in FIG. 6 .
- the left panels show the production levels in the case of (A) the addition of the nucleic acid alone to the medium
- the center panels show the production levels in the case of (B) the addition of the nucleic acid and DOTAP liposomal transfection reagent
- the right panels show the production levels in the case of (C) the addition of the nucleic acid and Lipofectamine 2000.
- the upper panels show TNF- ⁇ production
- the middle panels show IL-6 production
- the lower panels show IFN- ⁇ production.
- the data from three independent experiments were expressed as the mean value ⁇ SD.
- cM362-140, cM362-139 or poly(I:C) was intraperitoneally administered to wild-type C57BL/6J mice (9 weeks old, female) or TLR3KO mice (9 weeks old, female). Three mice were used per group.
- Each of the nucleic acids was prepared as a solution in RNase-free water. At 1 hour, 3 hours, and 6 hours after nucleic acid administration, the blood was collected from the tail vein, and the serum levels of TNF- ⁇ , IL-6 and IL-10 were measured. BD CBA Flex Set system was used for the measurement.
- the results are shown in FIG. 7 .
- the left panels show poly(I:C) administration, the center panels show cM362-139 administration, and the right panels show cM362-140 administration.
- the upper panels show TNF- ⁇ production, the middle panels show IL-6 production, and the lower panels show IL-10 production.
- the in vivo cytokine production levels induced by cM362-140 were markedly low as compared with those induced by poly(I:C). The results indicate that cM362-140 has no risk of causing adverse effects such as cytokine storm when administered to a living body and is highly safe.
- cM362-140 and OVA were at doses of 50 ⁇ g and 100 ⁇ g, respectively, and were prepared as a solution in PBS ( ⁇ ). The dosing volume was 50 ⁇ L. Seven days after the first administration (day 15 after implantation), the second administration was performed. Endotoxin-free OVA (Hyglos) was used as OVA.
- the results are shown in FIG. 8 .
- the cM362-140 single administration group induced barely any regression of the tumors, whereas the cM362-140+OVA administration group induced significant tumor regression (*: p ⁇ 0.05).
- the data were expressed as the mean value ⁇ SE, and the statistical analysis was performed by one-way ANOVA with Bonferroni's test.
- the tetramer assay was performed using spleen cells prepared from mice bearing EG7 tumors to evaluate the adjuvant activity of cM362-140.
- Spleen cells were prepared by the usual method seven days after the second administration of PBS, cM362-140 alone, OVA alone, or cM362-140+OVA in the above (1) (at day 22 after implantation).
- the spleen cells were dyed with FITC-CD8 ⁇ (BioLegend), PerCP/Cy5.5-7AAD (BD Biosciences), APC-CD3 ⁇ (BioLegend) and PE-OVA-Tetramer (MBL) to detect OVA-specific CD8 + T cells (tetramer + /CD8 + /CD3 + cells), and the proportion of the cells was calculated.
- the spleen cells prepared in the above (2) were seeded in 96-well culture plates (2 ⁇ 10 6 cells in 200 ⁇ L per well). The cells were cultured in the presence of 100 nM OVA peptide (SL8) for 3 days, and the IFN- ⁇ levels in the culture supernatants were measured by BD CBA Flex Set System.
- Example 6 The results in Example 6 indicate that cM362-140 induces the proliferation and activation of antigen-specific cytotoxic T cells, and serves as an effective adjuvant when used together with a cancer antigen.
- Wild-type C57BL/6J mice (WT) and TICAM-1 knockout mice (TICAM-1 KO, established by the inventors) were shaved at the back, and 6 ⁇ 10 5 B16 melanoma cells (B16D8) in 200 ⁇ L of PBS were subcutaneously implanted to establish tumors.
- Day 12 after implantation distilled water (DW) or 150 ⁇ g of cM362-140 mixed with in vivo-JetPEI was subcutaneously administered around the tumor. Three mice were used per group.
- the results are shown in FIG. 11 .
- the left panel shows tumor volumes in the wild-type mice, and the right panel shows tumor volumes in the TICAM-1 KO mice.
- significant tumor regression effect was observed in the wild-type mice that received cM362-140 compared with the group with distilled water (DW) administration.
- No tumor regression effect was observed in the TICAM-1 KO mice.
- the results indicate that the nucleic acid of the present invention exhibits its effect via TICAM-1-mediated signaling.
Abstract
Description
- The present invention relates to a novel adjuvant composition and a vaccine composition comprising the adjuvant composition.
- Most cancer immunotherapies are conducted by administering a peptide vaccine as a cancer antigen. For increased efficacy, co-administration of a cancer antigen with an adjuvant that activates dendritic cells has been proposed. The present inventors have advanced research on adjuvants for cancer immunotherapies, and found that measles viral diRNA (defective interference RNA) functions as an adjuvant. In particular, the inventors have found that the diRNA induces IFN-3 expression in human cells and enhances NK activity of NK cells, and that the diRNA administered together with a cancer antigen epitope induces marked tumor regression effect in cancer-bearing mice prepared by implanting B16 melanoma cells (Patent Literature 1). The inventors have also identified an oligo DNA that inhibits poly(I:C)-induced TLR3-mediated IFN-β expression, and reported that the oligo DNA shares the uptake receptor with poly(I:C) and the oligo DNA taken up in cells partially colocalized with TLR3 (Non Patent Literature 1). The inventors have designed a new nucleic acid based on the oligo DNA described in
Non Patent Literature 1 and the diRNA described inPatent Literature 1, and discovered that the nucleic acid reaches endosomal TLR3 and exhibits potent adjuvant activity (Patent Literature 2). - Nucleic acids with adjuvant activity supplied as pharmaceuticals must comply with the GMP standard, and are hence required to be prepared by chemical synthesis. However, chemical synthetic techniques for long RNAs, such as those longer than 100 mer, have not yet been established, and such RNAs are synthesized solely by in vitro transcription. Under these circumstances, development of a chemically synthesizable nucleic acid with potent adjuvant activity and high safety has been greatly desired to provide an adjuvant formulation as a pharmaceutical for humans.
-
- Patent Literature 1: WO 2008/065752
- Patent Literature 2: WO 2012/014945
-
- Non Patent Literature 1: The Journal of Immunology, 2008, 181: 5522-5529
- An object of the present invention is to provide an adjuvant composition comprising a chemically synthesizable nucleic acid having potent adjuvant activity and high safety, and a vaccine composition comprising the adjuvant composition and an antigen or an antigen component.
- The present invention was made to solve the above problems and includes the following.
- (1) An adjuvant composition comprising a double-stranded nucleic acid comprising a single-stranded nucleic acid A consisting of a nucleotide sequence of SEQ ID NO: 3 and a single-stranded nucleic acid B of SEQ ID NO: 4.
(2) The adjuvant composition according to the above (1), wherein the single-stranded nucleic acids A and B are chemically synthesized nucleic acids.
(3) The adjuvant composition according to the above (1) or (2), wherein the single-stranded nucleic acids A and B are formed of a plurality of chemically synthesized fragments linked by ligation.
(4) The adjuvant composition according to any one of the above (1) to (3), wherein the single-stranded nucleic acids A and B have no phosphate group attached to either of the ends.
(5) The adjuvant composition according to any one of the above (1) to (4), which comprises a single-stranded DNA whose nucleotides are all phosphorothioate modified.
(6) A vaccine composition comprising the adjuvant composition according to any one of the above (1) to (5) and an antigen or an antigen component.
(7) The vaccine composition according to the above (6), wherein the antigen is a cancer antigen. - The present invention provides an adjuvant composition comprising a chemically synthesized nucleic acid having potent adjuvant activity and high safety. The nucleic acid is more stable and has fewer adverse effects than a conventional nucleic acid produced by in vitro transcription, and is thus very useful as an adjuvant for humans. The adjuvant composition may be combined with an antigen or an antigen component to provide an effective vaccine composition.
-
FIG. 1A shows the structure of cM362-140, andFIG. 1B shows 7% urea-containing 8% PAGE of the sense and antisense RNAs of cM362-140. -
FIG. 2 shows the structure of cM362-139. -
FIGS. 3A and 3B show the stability of cM362-140 and cM362-139 in serum-containing PBS, respectively. -
FIGS. 4A and 4B show the stability of cM362-140 and cM362-139 in RNase-free water containing serum, respectively. -
FIG. 5 shows IFN-β promoter activation by cM362-140 as evaluated by reporter assay. -
FIG. 6 shows cytokine production induced by cM362-140 as evaluated in vitro using splenic dendritic cells from wild-type mice and TLR3 knockout mice. -
FIG. 7 shows cytokine production induced by intraperitoneal administration of cM362-140 to wild-type mice and TLR3 knockout mice as evaluated in vivo. -
FIG. 8 shows the tumor regression effect of cM362-140 and/or OVA in wild-type mice bearing EG7 cell tumors. -
FIG. 9 shows the detection of OVA-specific CD8+ T cells in spleen cells after administration of cM362-140 and/or OVA to wild-type mice bearing EG7 cell tumors. -
FIG. 10 shows the production levels of IFN-γ in spleen cells after administration of cM362-140 and/or OVA to wild-type mice bearing EG7 cell tumors. -
FIG. 11 shows the tumor regression effect of cM362-140 in mice (wild-type mice or TICAM-1 knockout mice) bearing B16 melanoma cell (B16D8) tumors. - The present invention provides an adjuvant composition comprising a nucleic acid comprising a double-stranded RNA bound to a single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2. The nucleic acid (hereinafter called “the nucleic acid of the present invention”) contained in the adjuvant composition of the present invention is only required to comprise the double-stranded RNA bound to the single-stranded DNA, the double-stranded RNA consisting of a nucleotide sequence of SEQ ID NO: 1 and its complementary sequence, the single-stranded DNA consisting of a nucleotide sequence of SEQ ID NO: 2. It has been demonstrated that the double-stranded RNA portion of the nucleic acid of the present invention has the ability to activate TLR3, and that the single-stranded DNA portion is delivered to the endosomal compartments of dendritic cells.
- Therefore, the nucleic acid of the present invention is efficiently delivered to the endosomal compartments of dendritic cells and activates TLR3, thereby stimulating the immune function.
- The nucleotide sequence of SEQ ID NO: 1 is the nucleotide residues at
positions 1 to 140 in the nucleotide sequence (SEQ ID NO: 5) of the sense strand of diRNA of measles virus laboratory-adapted strain of Edmonston (ED). The nucleotide sequence complementary to SEQ ID NO: 1 is indicated in SEQ ID NO: 4. The single-stranded DNA consisting of the nucleotide sequence of SEQ ID NO: 2 may be joined to either strand of the double-stranded RNA. The single-stranded DNA may be directly joined to the double-stranded RNA, or alternatively the single-stranded DNA and the double-stranded RNA may be joined together via another nucleic acid (e.g., a linker nucleic acid). Preferably, the single-stranded DNA is directly joined to the double-stranded RNA. The 3′ end of the single-stranded DNA may be joined to the 5′ end of the RNA, or alternatively the 5′ end of the single-stranded DNA may be joined to the 3′ end of the RNA. More preferably, the 3′ end of the single-stranded DNA is directly covalently bonded to the 5′ end of the RNA. Further preferably, the 3′ end of the single-stranded DNA is directly covalently bonded to the 5′ end of the RNA sense strand (SEQ ID NO: 1). That is, the nucleic acid of the present invention is preferably composed of the single-stranded nucleic acid A consisting of the nucleotide sequence of SEQ ID NO: 3 (a chimeric nucleic acid composed of the single-stranded DNA and the RNA sense strand) and the single-stranded nucleic acid B of SEQ ID NO: 4 (the RNA antisense strand). - The nucleotides of the single-stranded DNA are preferably phosphorothioate-modified nucleotides (also called “sulfur-modified nucleotides”). Part or all of the nucleotides of the single-stranded DNA may be phosphorothioate modified, but preferably all of the nucleotides of the single-stranded DNA are phosphorothioate modified. Phosphorothioate modification increases nuclease resistance and enhances delivery to endosomal compartments.
- The nucleic acid of the present invention is preferably formed of two nucleic acid strands produced by chemical synthesis. That is, the above single-stranded nucleic acids A and B are preferably chemically synthesized nucleic acid strands. Unlike conventional long RNAs synthesized by in vitro transcription, the nucleic acid of the present invention is produced by sequence-specific chemical synthesis, and thus is highly useful due to several advantages: for example, the nucleic acid of the present invention can be provided in a stable, lyophilized form, and has a correctly synthesized nucleotide sequence. The chemical synthesis method of the nucleic acid is not particularly limited, and a conventionally known chemical synthesis method can be appropriately used. Examples of the conventional method include the phosphoramidite method etc.
- Each of the single-stranded nucleic acids may be chemically synthesized as a full-length nucleic acid. Alternatively, several fragments of each nucleic acid may be separately synthesized and linked by ligation to give the nucleic acid. The length (the number of bases) of each fragment is not particularly limited, but is preferably about 30 mer to about 80 mer, more preferably about 35 mer to about 70 mer, further preferably about 40 mer to about 60 mer. The ligation may be performed by a known ligation technique, and is preferably performed by ligation reaction mediated by a splint DNA, as described in, for example, Moore et al. (Moore M J, & Sharp P A. Site-specific modification of pre-mRNA: the 2′-hydroxyl groups at the splice sites. Science 256: 992-997 (1992)) and Jing et al. (Jing Xu, Lapham J, & Crothers D M. Determining RNA solution structure by segmental isotopic labeling and NMR: Application to Caenorhabditis elegans spliced
leader RNA 1. Proc. Natl. Acad. Sci. USA 93: 44-48 (1996)) (see Example 1). - Each of the single-stranded nucleic acids that are combined together to form the nucleic acid of the present invention preferably has no phosphate group at either of the ends. In in vitro transcription, synthesized RNA strands have triphosphoric acid attached to the 5′ end, but since the nucleic acid of the present invention is produced by chemical synthesis, the single-stranded nucleic acids that are combined together to form the nucleic acid of the present invention have no phosphate group at the 5′ end or the 3′ end. If a nucleic acid having a phosphate group attached to the 5′ end is administered to a living body at a high dose, the nucleic acid will activate the cytoplasmic RIG-I pathway to induce the production of a large amount of cytokines, and in turn will cause adverse effects (Robinson R A, DeVita V T, Levy H B, Baron S, Hubbard S P, Levine A S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst. 1976 September; 57(3): 599-602). In contrast, the nucleic acid of the present invention can be used to provide a highly safe adjuvant composition.
- Unlike poly(I:C), the nucleic acid of the present invention preferentially activates the TICAM-1-mediated signaling system downstream of TLR3, and does not activate the intracellular RNA sensors other than TLR3. Hence, the nucleic acid of the present invention has been confirmed to have no risk of inducing cytokine storm and to be thus highly safe (see Examples 5 and 7). The nucleic acid of the present invention has also been confirmed to be more stable than a nucleic acid with a similar structure formed of RNA strands synthesized by in vitro transcription (see Example 2).
- As described above, the nucleic acid of the present invention is delivered to the endosomal compartments of dendritic cells and activates TLR3, thereby enhancing various immune responses. The nucleic acid of the present invention is highly safe and stable, and is thus very useful as an active ingredient of an adjuvant composition. The adjuvant composition of the present invention can be formulated into a dosage form by appropriately blending the nucleic acid of the present invention with a pharmaceutically acceptable carrier or additive. In particular, the adjuvant composition can be formulated into an oral formulation, such as a tablet, a coated tablet, a pill, a powder, granules, a capsule, a solution, a suspension and an emulsion, or a parenteral formulation, such as an injection, an infusion, a suppository, an ointment and a patch. The amount of the carrier or additive to be added can be determined as appropriate based on the range typically used in the pharmaceutical field. The carrier or additive that may be added is not particularly limited and examples thereof include various types of carriers, such as water, physiological saline, other aqueous solvents, and aqueous or oily vehicles; and various types of additives, such as excipients, binders, pH adjusters, disintegrants, absorption promoters, lubricants, colorants, flavors and fragrances.
- Examples of the additives that may be added to a tablet, a capsule, etc. include binders such as gelatin, corn starch, tragacanth and gum arabic; excipients such as crystalline cellulose; swelling agents such as corn starch, gelatin, and alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose and saccharin; and flavors such as peppermint flavor, wintergreen oil and cherry flavor. When the unit dosage form is a capsule, a liquid carrier such as oils and fats can be further added in addition to the above types of ingredients. A sterile composition for injection can be formulated in accordance with the usual pharmaceutical practice, for example, by dissolving or suspending the active ingredient in a vehicle, such as water for injection, or a natural vegetable oil, such as sesame oil and coconut oil. An aqueous liquid for injection that may be used is, for example, physiological saline or an isotonic solution containing glucose and/or other auxiliary substances (for example, D-sorbitol, D-mannitol, sodium chloride, etc.). The aqueous liquid for injection may be used in combination with an appropriate solubilizer, such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (e.g.,
polysorbate 80™, HCO-50, etc.). An oily liquid that may be used is, for example, sesame oil or soybean oil. The oily liquid may be used in combination with a solubilizer such as benzyl benzoate and benzyl alcohol. Other additives that may be added are, for example, buffering agents (e.g., a phosphate buffer, a sodium acetate buffer, etc.), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives (e.g., benzyl alcohol, phenol, etc.) and antioxidants. - The formulations produced in the above manner can be administered to, for example, humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.). The dose and dosing frequency of the adjuvant composition of the present invention can be determined, as appropriate, in accordance with the purpose of administration, the age, body weight, sex and past medical history of the subject, the mode of administration, etc.
- The present invention also provides a vaccine composition comprising the adjuvant composition of the present invention and an antigen or an antigen component. Examples of the antigen or the antigen component include a viral antigen, a bacterial antigen, a cancer antigen, a component thereof, etc. Preferred is a cancer antigen. Combined administration of the nucleic acid of the present invention and a cancer antigen has been revealed to induce marked tumor regression in tumor-bearing mice prepared by subcutaneously implanting cancer cells. Thus, the vaccine composition of the present invention has been confirmed to be very useful as a cancer vaccine. The vaccine composition of the present invention can be produced by adding an antigen or an antigen component to the adjuvant composition of the present invention. The vaccine composition of the present invention can be formulated into a dosage form in the same manner as in the dosage formulation of the adjuvant composition of the present invention.
- Examples of the viral antigen include, for example, viral antigens from adenovirus, retrovirus, picornavirus, herpesvirus, rotavirus, hantavirus, coronavirus, togavirus, flavivirus, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, reovirus, papillomavirus, parvovirus, poxvirus, hepadnavirus, spongiform virus, HIV, CMV, hepatitis A virus, hepatitis B virus, hepatitis C virus, influenza virus, measles virus, poliovirus, smallpox virus, rubella virus, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, Japanese encephalitis virus, rabies virus, influenza virus, etc., or a combination thereof.
- Examples of the bacterial antigen include, for example, bacterial antigens from Bacillus spp., Escherichia spp., Listeria spp., Neisseria spp., Nocardia spp., Salmonella spp., Staphylococcus spp., Streptococcus spp., etc., or a combination thereof.
- Examples of the cancer antigen include, for example, cancer antigens from leukemia, lymphoma, astrocytoma, glioblastoma, melanoma, breast cancer, lung cancer, head and neck cancer, digestive system tumors, stomach cancer, colon cancer, liver cancer, pancreatic cancer, uterine cancer, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer, penile cancer, bone tumors, blood vascular tumors, esophageal cancer, stomach cancer, rectal cancer, large intestine cancer, pancreatic cancer, gall bladder cancer, bile duct cancer, laryngeal cancer, lung cancer, bronchial cancer, bladder cancer, renal cancer, brain tumors, thyroid cancer, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, etc., or a combination thereof.
- The present invention further includes the following.
- (1) A nucleic acid formed of the single-stranded nucleic acid A consisting of the nucleotide sequence of SEQ ID NO: 3 and the single-stranded nucleic acid B of SEQ ID NO: 4.
(2) A method for treating a cancer, comprising administering the nucleic acid according to the above (1) and a cancer antigen to a mammal.
(3) The nucleic acid according to the above (1) for use in the treatment of a cancer.
(4) Use of the nucleic acid according to the above (1) for the production of a therapeutic drug for a cancer. - The present invention will be described in more detail below with reference to Examples, but the present invention is not limited thereto.
- (1) Preparation of cM362-140 (Chemically Synthesized Nucleic Acid)
- The single-stranded nucleic acids (S1, S2, S3, AS1, AS2 and AS3) shown in Table 1 were synthesized by GeneDesign, Inc. The RNA fragments were chemically synthesized using tBDMS RNA amidites, the DNA fragment was chemically synthesized using standard DNA amidites, and phosphorothioate linkages (sulfur modification) were introduced using PADS. The synthesis was performed based on the phosphoramidite method (Scaringe, S. A. et al, J Am Chem 1998; 120: 11820-11821) using a solid-phase carrier with optimized parameters. After completion of the synthesis, the protecting groups on the bases and on the 2′ position were removed by the usual method. The products were purified by reverse-phase HPLC and desalted to give the single-stranded nucleic acids.
-
TABLE 1 Fragment RNA Sense MV-RNA sequence Antisense MV-RNA sequence S1 (SEQ ID NO: 6) 5′-t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}a{circumflex over ( )}a{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}a{circumflex over ( )}g{circumflex over ( )} c{circumflex over ( )}t{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}a{circumflex over ( )}t{circumflex over ( )} + MV(ED)DI RNA 1-14 S2 (SEQ ID NO: 7) 5′-p + MV(ED)DI RNA 15-74 S3 (SEQ ID NO: 8) 5′-p + MV(ED)DI RNA 75-140 AS1 (SEQ ID NO: 9) MV(ED)DI RNA 1013-1064 AS2 (SEQ ID NO: 10) 5′-p + MV(ED)DI RNA 1065-1104 AS3 (SEQ ID NO: 11) 5′-p + MV(ED)DI RNA 1105-1152 Bases in lower-case letters are oligodeoxpucleotides. {circumflex over ( )}, phosphorothioate; 5′-p, 5′ phosphate. - The chemically synthesized long RNA cM362-140 was constructed by ligation reactions mediated by a splint DNA as described below (references: Moore M J & Sharp P A. Site-specific modification of pre-mRNA: the 2′-hydroxyl groups at the splice sites. Science 256: 992-997 (1992), and Jing Xu, Lapham J, & Crothers D M. Determining RNA solution structure by segmental isotopic labeling and NMR: Application to Caenorhabditis elegans spliced
leader RNA 1. Proc. Natl. Acad. Sci. USA 93: 44-48 (1996)). - To prepare the sense RNA (single-stranded nucleic acid A) of cM362-140, the ligation reactions were performed in two steps. As the first ligation, S2 fragment (SEQ ID NO: 7, 40 nmol), S3 fragment (SEQ ID NO: 8, 40 nmol) and a splint DNA (SEQ ID NO: 12, 40-48 nmol) specific for the ligation site were mixed, heated at 95° C. for 5 minutes and then slowly cooled to 4° C. to allow hybridization to take place. T4 DNA ligase (Takara Bio) was added and the mixture was incubated at room temperature for 16 to 22 hours. The ligation reaction mixture contained 15.4 M annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl2, 10 mM DTT, 0.1 mM ATP and ˜31 U/μL T4 DNA ligase. As the second ligation, S1 fragment (SEQ ID NO: 6, 40 nmol) and a splint DNA (SEQ ID NO: 13, 40-48 nmol) specific for the second ligation site were added to the first ligation reaction mixture, and hybridized in the same manner as in the first ligation. T4 DNA ligase was added and the mixture was incubated at room temperature for 16 to 22 hours. The second ligation reaction mixture contained 8.9 μM annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl2, 10 mM of DTT, 0.1 mM of ATP and ˜31 U/L T4 DNA ligase. The derived full-
length 165 mer sense RNA (single-stranded nucleic acid A) was isolated by 8% PAGE containing 7 M urea. After visualization by UV irradiation, the band of interest was excised and eluted with 0.3 M sodium acetate. The eluted RNA was ethanol precipitated and resuspended in RNase-free water. For large-scale preparation of the RNA, electro-elution was performed using D-tube Dialyzer Maxi (Novagen) and eluted RNA was dialyzed, concentrated and precipitated with ethanol. The concentration of RNA was determined by measuring the absorbance at 260 nm in a spectrometer. The yield was 8 to 10%. - To prepare the antisense RNA (single-stranded nucleic acid B) of cM362-140, three fragments, AS1 (SEQ ID NO: 9, 33 nmol), AS2 (SEQ ID NO: 10, 33 nmol) and AS3 (SEQ ID NO: 11, 33 nmol) and two splint DNAs (SEQ ID NOs: 14 and 15, 33 nmol each) specific for two different ligation sites were mixed, and hybridized. T4 DNA ligase was added and the mixture was incubated at room temperature for 16 to 22 hours. The ligation reaction mixture contained 15 μM annealed complex, 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl2, 10 mM DTT, 0.1 mM ATP and ˜31 U/L T4 DNA ligase. The derived full-
length 140 mer antisense RNA (single-stranded nucleic acid B) was purified by the same procedure as in the preparation of the sense RNA. The yield was 15 to 22%. - To generate cM362-140, the sense RNA (single-stranded nucleic acid A) and the antisense RNA (single-stranded nucleic acid B) were annealed.
FIG. 1A shows the structure of cM362-140, andFIG. 1B shows 8% PAGE of the 165 mer sense RNA (single-stranded nucleic acid A) and the 140 mer antisense RNA (single-stranded nucleic acid B) synthesized above. The sense and antisense RNAs were each detected as a single band with a size consistent with the nucleotide length. - (2) Preparation of Control Nucleic Acid cM362-139
- The structure of cM362-139 is shown in
FIG. 2 , and the nucleotide sequence of cM362-139 is shown in Table 2. -
TABLE 2 DNA sequence of ODN (sODN and linker DNA) (SEQ ID NO: 16) 5′-t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}a{circumflex over ( )}a{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}a{circumflex over ( )}g{circumflex over ( )}c{circumflex over ( )}t{circumflex over ( )}t{circumflex over ( )}g{circumflex over ( )}a{circumflex over ( )}t{circumflex over ( )} accgtggtcatgctcc-3′ Sense MV-RNA sequence (SEQ ID NO: 17) Antisense MV-RNA sequence (SEQ ID NO: 18) GGG + MV (ED) DI RNA 1-136 MV (ED) DI RNA 1017-1152 + cccggagcaugaccacgg {circumflex over ( )}: phosphorothioate - The single-stranded DNA (ODN+linker DNA) was synthesized by GeneDesign, Inc. The defective interference RNA (diRNA) of measles virus (MV) laboratory-adapted strain of Edmonston (ED) was used as the template of the double-stranded RNA. DNA fragments covering this region of the MV genome and the T7 promoter sequence were amplified by PCR using the plasmid pCR-T7 MV as a template. The primers used are shown below.
-
ODN-139 sense RNA (5′ primer) (SEQ ID NO: 19) 5′-tgtaatacgactcactatagggaccagacaaagctggga-3′ - T7 promoter sequence is underlined.
-
ODN-139 sense RNA (3′ primer) (SEQ ID NO: 20) 5′-ggatacagtgccctgattaa-3′ ODN-139 antisense RNA (5′ primer) (SEQ ID NO: 21) 5′-tgtaatacgactcactataggatacagtgccctgattaa-3′ - T7 promoter sequence is underlined.
-
ODN-139 antisense RNA (3′ primer) (SEQ ID NO: 22) 5′-ccgtggtcatgctccgggaccagacaaagctggga-3′ - The sense and antisense RNAs were in vitro transcribed from the PCR products using AmpliScribe™ T7 transcription kit (Epicentre Technologies) in accordance with the manufacturer's protocol. The transcribed products were isolated by 8% PAGE containing 7 M urea and purified in the same manner as in Example 1. Finally, the single-stranded DNA (ODN+linker DNA) and the sense and antisense RNAs were mixed and annealed to give cM362-139.
- cM362-140 and cM362-139 were separately dissolved at 20 μg/mL in serum-free PBS, PBS containing 10% heat-inactivated fetal bovine serum (FBS), PBS containing 10% mouse serum (MS) or PBS containing 10% human serum (HS), and incubated at 37° C. or 42° C. for 60 minutes. Aliquots containing 0.1 μg of the treated nucleic acids were taken before start of incubation (0 minute-incubation, only for serum-free PBS) and after 5-, 15-, 30- and 60-minute incubation, mixed with 10× loading dye (Takara Bio), and electrophoresed on 4% agarose gel (Nusieve 3:1 Agarose, Lonza) containing ethidium bromide.
- The results are shown in
FIGS. 3A and 3B .FIGS. 3A and 3B show the electrophoretic patterns of cM362-140 and cM362-139, respectively. Both nucleic acids were stable during the 30-minute incubation at 37° C., but cM362-139, which was prepared by in vitro transcription, was slightly degraded during the 30-minute incubation in PBS containing serum (FBS, MS or HS) at 42° C. - The stability of the nucleic acids was examined by electrophoresis on 3% agarose gel using RNase-free water instead of PBS under the same conditions as above.
- The results are shown in
FIGS. 4A and 4B .FIGS. 4A and 4B show the electrophoretic patterns of cM362-140 and cM362-139, respectively. cM362-140 was stable under all the conditions, but cM362-139 was slightly degraded during incubation in the presence of serum (FBS, MS or HS). - Thus, cM362-140 was found to be more stable than cM362-139.
- HEK293 cells (8×105 cells/well) were seeded in 6-well culture plates. The HEK293 cells were transfected with a human TLR3 expression vector (400 ng/well) or an empty vector (400 ng/well) together with a reporter plasmid p-125 (400 ng/well) and an internal control vector phRL-TK (20 ng/well, Promega) using Lipofectamine 2000 (Invitrogen). The reporter plasmid p-125 containing the human IFN-β promoter region (−125 to +19) was provided by Dr. Taniguchi (the University of Tokyo). Dulbecco's Modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FCS, Invitrogen) and antibiotics was used as medium.
- Twenty-four hours after transfection, the cells were recovered, resuspended in medium and seeded in 96-well culture plates. The nucleic acids, i.e., cM362-140, cM362-139, poly(I:C) (Amersham) and the double-stranded RNA portion (dsRNA140) of cM362-140, were separately added to a concentration of 10 μg/mL in the following manner:
- (A) each nucleic acid was directly added to medium containing HEK293 cells expressing human TLR3,
(B) each nucleic acid and DOTAP liposomal transfection reagent (Roche) were added to medium containing HEK293 cells expressing human TLR3, or
(C) each nucleic acid and Lipofectamine 2000 (Invitrogen) were added to medium containing HEK293 cells. - Dual-Luciferase Reporter Assay System (Promega) was used for luciferase activity measurement. The luciferase activity was measured 6 hours after addition of the nucleic acids in (A) and (B) and 24 hours after addition of the nucleic acids in (C).
- The results are shown in
FIG. 5 . The left panel shows the results of (A), the center panel shows the results of (B) and the right panel shows the results of (C). The data were expressed as the mean value±SD (n=3). cM362-140 efficiently induced IFN-β promoter activation similar to cM362-139 in (A) the simple addition of cM362-140 to the extracellular matrix (medium) of the HEK293 cells expressing human TLR3, and in (B) the endosomal delivery of cM362-140 to the HEK293 cells expressing human TLR3 (FIG. 5 , left and center panels). Activation of the IFN-β promoter was not observed in (C) the cytoplasmic delivery of cM362-140 to the HEK293 cells not expressing human TLR3. The results indicate that cM362-140 induces TLR3-mediated IFN-β promoter activation but does not induce other IFN-β promoter activation via other RNA/DNA sensors. - The spleen was harvested from wild-type C57BL/6J mice (WT) and TLR3 knockout mice (TLR3KO) (provided by Dr. Akira, Osaka University), and treated with collagenase. The splenocyte suspension was passed through a filter, erythrocytes were lysed, and the splenocytes were washed with medium. The splenocytes were subjected to MACS system (Miltenyi Biotech) using anti-CD11c microbeads to isolate CD11c+ cells as splenic DCs. Dulbecco's Modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FCS, Invitrogen) and antibiotics was used as medium. All the animal experiments herein were performed according to the guideline issued by the Hokkaido University Animal Care and Use Committee.
- The splenic DCs were seeded at 5×105 cells in 500 μL of medium per well in 24-well plates, then 20 μg/mL nucleic acid (cM362-140, cM362-139, poly(I:C), or dsRNA140) was added (A) alone, (B) together with DOTAP liposomal transfection reagent (Roche), or (C) together with Lipofectamine 2000 (Invitrogen), and the cells were cultured for 24 hours. After 24 hours of culture, the culture supernatants were recovered, and the production levels of TNF-α, IL-6 and IFN-β were measured. BD CBA Flex Set system was used for measurement of TNF-α and IL-6, and Mouse IFN-β ELISA Kit (PBL Assay Science) was used for measurement of IFN-3.
- The results are shown in
FIG. 6 . The left panels show the production levels in the case of (A) the addition of the nucleic acid alone to the medium, the center panels show the production levels in the case of (B) the addition of the nucleic acid and DOTAP liposomal transfection reagent, and the right panels show the production levels in the case of (C) the addition of the nucleic acid andLipofectamine 2000. The upper panels show TNF-α production, the middle panels show IL-6 production, and the lower panels show IFN-β production. The data from three independent experiments were expressed as the mean value ±SD. As is clear from the results shown in the left panels, extracellular addition of cM362-140 alone to the splenic DCs induced a subtle increase in TNF-α, IL-6 and IFN-β production in the splenic DCs from the wild-type mice. As shown in the results in the center panels, endosomal delivery of cM362-140 using DOTAP liposomal transfection reagent induced an increase in TNF-α, IL-6 and IFN-β production in the splenic DCs from the wild-type mice. On the other hand, as apparent from the results in the right panels, when cM362-140 was delivered to thecytoplasm using Lipofectamine 2000, the production levels of TNF-α, IL-6 and IFN-β were lower than those in the endosomal delivery. No induction of cytokine production by cM362-140 was observed in the splenic DCs from the TLR3KO mice in either delivery condition. The results indicate that cM362-140 targets the endosomal TLR3, but does not target the cytoplasmic RNA/DNA sensors. - Fifty micrograms of cM362-140, cM362-139 or poly(I:C) was intraperitoneally administered to wild-type C57BL/6J mice (9 weeks old, female) or TLR3KO mice (9 weeks old, female). Three mice were used per group. Each of the nucleic acids was prepared as a solution in RNase-free water. At 1 hour, 3 hours, and 6 hours after nucleic acid administration, the blood was collected from the tail vein, and the serum levels of TNF-α, IL-6 and IL-10 were measured. BD CBA Flex Set system was used for the measurement.
- The results are shown in
FIG. 7 . The left panels show poly(I:C) administration, the center panels show cM362-139 administration, and the right panels show cM362-140 administration. The upper panels show TNF-α production, the middle panels show IL-6 production, and the lower panels show IL-10 production. The data were expressed as the mean value±SE (n=3). As apparent fromFIG. 7 , the in vivo cytokine production levels induced by cM362-140 were markedly low as compared with those induced by poly(I:C). The results indicate that cM362-140 has no risk of causing adverse effects such as cytokine storm when administered to a living body and is highly safe. - C57BL/6J mice were shaved at the back, and 2×106 EG7 cells (cancer cells established from EL4 cells from thymic carcinoma of C57BL/6 mice by forced expression of ovalbumin antigen) in 200 μL of PBS were subcutaneously implanted to establish tumors. Tumor volumes (cm3=(long diameter)×(short diameter)2×0.4) were measured over time.
Day 8 after implantation (tumor volume: about 0.6 cm3), cM362-140 alone, OVA alone, or cM362-140+OVA was subcutaneously administered around the tumor. As a control, PBS (−) alone was administered in the same manner. Four mice were used per group. cM362-140 and OVA were at doses of 50 μg and 100 μg, respectively, and were prepared as a solution in PBS (−). The dosing volume was 50 μL. Seven days after the first administration (day 15 after implantation), the second administration was performed. Endotoxin-free OVA (Hyglos) was used as OVA. - The results are shown in
FIG. 8 . The cM362-140 single administration group induced barely any regression of the tumors, whereas the cM362-140+OVA administration group induced significant tumor regression (*: p<0.05). The data were expressed as the mean value ±SE, and the statistical analysis was performed by one-way ANOVA with Bonferroni's test. - The tetramer assay was performed using spleen cells prepared from mice bearing EG7 tumors to evaluate the adjuvant activity of cM362-140. Spleen cells were prepared by the usual method seven days after the second administration of PBS, cM362-140 alone, OVA alone, or cM362-140+OVA in the above (1) (at day 22 after implantation). The spleen cells were dyed with FITC-CD8α (BioLegend), PerCP/Cy5.5-7AAD (BD Biosciences), APC-CD3ε (BioLegend) and PE-OVA-Tetramer (MBL) to detect OVA-specific CD8+ T cells (tetramer+/CD8+/CD3+ cells), and the proportion of the cells was calculated.
- The results are shown in
FIG. 9 . As is clear fromFIG. 9 , the proportion of OVA-specific CD8+ T cells in spleen cells was significantly large in the cM362-140+OVA administration group, as compared with those in the other groups (**: p<0.01). The statistical analysis was performed by one-way ANOVA with Bonferroni's test. - The spleen cells prepared in the above (2) were seeded in 96-well culture plates (2×106 cells in 200 μL per well). The cells were cultured in the presence of 100 nM OVA peptide (SL8) for 3 days, and the IFN-γ levels in the culture supernatants were measured by BD CBA Flex Set System.
- The results are shown in
FIG. 10 . As is clear fromFIG. 10 , the IFN-γ production level in spleen cells was significantly large in the cM362-140+OVA administration group, as compared with those in the other groups (**: p<0.01). The data were expressed as the mean value ±SE, and the statistical analysis was performed by one-way ANOVA with Bonferroni's test. - The results in Example 6 indicate that cM362-140 induces the proliferation and activation of antigen-specific cytotoxic T cells, and serves as an effective adjuvant when used together with a cancer antigen.
- Regression of implanted cancer induced by activation of NK cells was evaluated using a C57BL/6-B16 syngeneic NK-sensitive tumor-implant model (Akazawa T., T. Ebihara, M. Okuno, Y. Okuda, K. Tsujimura, T. Takahashi, M. Ikawa, M. Okabe, T. Ebihara, M. Shingai, N. Inoue, M. Tanaka-Okamoto, H. Ishizaki, J. Miyoshi, M. Matsumoto, and T. Seya. 2007. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA. 104: 252-257.). Wild-type C57BL/6J mice (WT) and TICAM-1 knockout mice (TICAM-1 KO, established by the inventors) were shaved at the back, and 6×105 B16 melanoma cells (B16D8) in 200 μL of PBS were subcutaneously implanted to establish tumors. Tumor volumes (cm3=(long diameter)×(short diameter)2×0.4) were measured over time.
Day 12 after implantation, distilled water (DW) or 150 μg of cM362-140 mixed with in vivo-JetPEI was subcutaneously administered around the tumor. Three mice were used per group. - The results are shown in
FIG. 11 . The left panel shows tumor volumes in the wild-type mice, and the right panel shows tumor volumes in the TICAM-1 KO mice. As apparent fromFIG. 11 , significant tumor regression effect was observed in the wild-type mice that received cM362-140 compared with the group with distilled water (DW) administration. No tumor regression effect was observed in the TICAM-1 KO mice. The results indicate that the nucleic acid of the present invention exhibits its effect via TICAM-1-mediated signaling. - The present invention is not limited to each of the embodiments and Examples described above, and various modifications are possible within the scope of the claims. Embodiments obtainable by appropriately combining the technical means disclosed in the different embodiments of the present invention are also included in the technical scope of the present invention. The contents of the scientific literature and the patent literature cited herein are hereby incorporated by reference in their entirety.
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014244421A JP6453063B2 (en) | 2014-12-02 | 2014-12-02 | Adjuvant composition |
JP2014-244421 | 2014-12-02 | ||
PCT/JP2015/083825 WO2016088784A1 (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180280425A1 true US20180280425A1 (en) | 2018-10-04 |
US10105385B1 US10105385B1 (en) | 2018-10-23 |
Family
ID=56091725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/531,671 Active US10105385B1 (en) | 2014-12-02 | 2015-12-01 | Adjuvant composition |
Country Status (7)
Country | Link |
---|---|
US (1) | US10105385B1 (en) |
EP (1) | EP3228322B8 (en) |
JP (1) | JP6453063B2 (en) |
CN (1) | CN106999573B (en) |
AU (1) | AU2015356078B2 (en) |
CA (1) | CA2969024C (en) |
WO (1) | WO2016088784A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11065331B2 (en) | 2016-07-27 | 2021-07-20 | Advanced Innovation Development Co. Ltd. | Immune adjuvant for cancer |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109963584B (en) | 2016-09-06 | 2024-03-15 | 豪夫迈·罗氏有限公司 | Peptide arrays that bind MHC and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1177927C (en) * | 1998-03-26 | 2004-12-01 | 惠氏控股有限公司 | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B |
JPWO2008065752A1 (en) * | 2006-11-30 | 2010-03-04 | 国立大学法人北海道大学 | Immunotherapeutic drug containing diRNA |
EP2085479A1 (en) * | 2008-01-31 | 2009-08-05 | Institut Pasteur | Reverse genetics of negative-strand rna viruses in yeast |
US9090650B2 (en) | 2010-07-28 | 2015-07-28 | National University Corporation Hokkaido University | Nucleic acid having adjuvanticity and use thereof |
CN102000330B (en) * | 2010-09-14 | 2012-08-29 | 中国人民解放军第二军医大学 | Nucleic acid vaccine adjuvant and construction method thereof |
-
2014
- 2014-12-02 JP JP2014244421A patent/JP6453063B2/en active Active
-
2015
- 2015-12-01 CN CN201580065778.3A patent/CN106999573B/en active Active
- 2015-12-01 WO PCT/JP2015/083825 patent/WO2016088784A1/en active Application Filing
- 2015-12-01 US US15/531,671 patent/US10105385B1/en active Active
- 2015-12-01 EP EP15865520.9A patent/EP3228322B8/en active Active
- 2015-12-01 CA CA2969024A patent/CA2969024C/en active Active
- 2015-12-01 AU AU2015356078A patent/AU2015356078B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11065331B2 (en) | 2016-07-27 | 2021-07-20 | Advanced Innovation Development Co. Ltd. | Immune adjuvant for cancer |
Also Published As
Publication number | Publication date |
---|---|
JP2016108250A (en) | 2016-06-20 |
CA2969024C (en) | 2022-05-24 |
EP3228322A1 (en) | 2017-10-11 |
CN106999573B (en) | 2021-10-19 |
US10105385B1 (en) | 2018-10-23 |
EP3228322B8 (en) | 2019-06-19 |
JP6453063B2 (en) | 2019-01-16 |
WO2016088784A1 (en) | 2016-06-09 |
CA2969024A1 (en) | 2016-06-09 |
CN106999573A (en) | 2017-08-01 |
EP3228322A4 (en) | 2018-05-30 |
EP3228322B1 (en) | 2019-04-10 |
AU2015356078A1 (en) | 2017-06-29 |
AU2015356078B2 (en) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102623786B1 (en) | Compositions and methods of treating muscle atrophy and myotonic dystrophy | |
JP7032577B2 (en) | Peptide-nucleic acid complex capable of escape from endosomes and its uses | |
JP2021512090A (en) | Compositions and Methods for Delivering Drugs to Immune Cells | |
US9090650B2 (en) | Nucleic acid having adjuvanticity and use thereof | |
JP2022523794A (en) | Cyclic polyribonucleotide and pharmaceutical composition thereof | |
US11931409B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
EP4259796A1 (en) | Therapeutics for the treatment of neurodegenerative disorders | |
US10105385B1 (en) | Adjuvant composition | |
Meng et al. | Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy | |
JP2024503623A (en) | Encapsulated RNA polynucleotides and methods of use | |
KR20200028392A (en) | STING-dependent activator for the treatment of diseases | |
US11713463B2 (en) | Compositions and methods for increasing expression of SCN2A | |
JP6829443B2 (en) | Anti-cancer drug containing HVJ-E and CXCL2 | |
WO2023092060A1 (en) | Microrna-dependent mrna switches for tissue-specific mrna-based therapies | |
WO2023056418A1 (en) | Lipid nanoparticle (lnp) compositions and methods of use thereof | |
WO2023107920A1 (en) | Anisamide-containing lipids and compositions and methods of use thereof | |
WO2023104964A1 (en) | Therapeutics for the treatment of neurodegenerative disorders | |
WO2023092040A1 (en) | Spherical nucleic acids for cgas-sting and stat3 pathway modulation for the immunotherapeutic treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSIT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEYA, TSUKASA;MATSUMOTO, MISAKO;REEL/FRAME:042636/0609 Effective date: 20170530 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: ADVANCED INNOVATION DEVELOPMENT CO. LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY;REEL/FRAME:049247/0206 Effective date: 20190417 |
|
AS | Assignment |
Owner name: INSTITUTE OF ADVANCED IMMUNOTHERAPY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED INNOVATION DEVELOPMENT CO. LTD.;REEL/FRAME:058157/0070 Effective date: 20210812 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |